Articles On Memphasys (ASX:MEM)

 The ASX 200 benchmark has climbed down from highs at lunch to finish on +0.39%. Health Care was well out in front of the market all day, thanks to a chunky bump for CSL. Voltaic Strategic Resources won the Small Caps Cup, rising 22.5% for...

ASX benchmark falls 0.86% for the day, dragged down by bad news from China. Telcos, Energy and InfoTech tried their best, but the overall gloom was too much to fight. Lithium Universe (ASX:LU7) banks a solid market debut as it kicks off i...

Just a week into its pivotal deal with global IVF provider Vitrolife, reproductive biotechnology company Memphasys has already received its first order to put its patented Felix system into clinics in Japan.

Firebrick achieved primary endpoint in Phase 2 Memphasys rise 20pc after distribution deal in Japan Clarity Pharma says ‘pre-targeting’ presents groundbreaking avenue   Firebrick achieves primary endpoint in Phase 2 Firebrick Pharma (ASX:...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The ASX will open lower on Monday Wall Street megacaps mainly fell on Friday This week’s focus will be on US CPI data   The ASX 200 is set to open lower on Monday and extend its 1% loss last week. At 8am AEST, the ASX 200 index futures wa...

Reproductive technology specialist Memphasys has inked an exclusive five-year distribution deal with Vitrolife – a global provider of human IVF medical devices – to sell its patented Felix system in Japan.

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Reproductive biotechnology company Memphasys been granted two new Australian patents for its flagship Felix system, ensuring that the integrity of its IVF treatment device is protected in all markets.

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

The ASX fell this morning and – sadly – just never recovered. It’s down 0.64%. Aside from Happy Times among the lithium players, it’s been a total snoozefest Rubix Resources (ASX:RB6) takes bragging rights with a 41.6% hike for the day  ...

S&P/ASX 200 closes up 0.6%, while the emerging companies index rises 0.86% Austral’s US subsidiary Austral USA awarded a contract worth up to US$3.195 billion from the US Navy Pushpay ceases trading on the ASX and NZX following its $1....

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Despite the materials sector having a tough run today on the back of lower gold, silver and copper prices, many small- and mid-caps in this space are making headway. Dreadnought Resources (DRE) has defined a wide zone of rare earth eleme...

Memphasys (MEM) reports the first live birth of a healthy baby boy in India using its Felix system at the Coimbatore Women’s Hospital Centre However, Memphasys has temporarily suspended sales of Felix into the country following changes...

Aussie shares to extend gains on Monday after a rally in New York EU inflation continues to be at record high Oil prices spiked 7pc as OPEC+ announced cuts   Aussie shares are set to open higher again on Monday, tracking stocks in New Yor...

The ASX is expected to open the new week higher ahead of the much-anticipated RBA rates decision on Tuesday. ASX futures were also up over the weekend. Here are some ASX-listed companies to look out for during Monday’s trade: Dreadnou...

What’s wrong with our tadpoles, gentlemen? According to local fertility expert Prof John Aitken, sperm counts have roughly halved over the last 50 years and about 20 per cent of men shoot blanks. No-one’s sure why, but possible reasons incl...

The ASX extended the week’s losses by falling 0.4% today Star Entertainment Group posted a loss so large it almost defies description Mt Monger has had a fantastic day, up 46.6% after joining the Great Canadian REE Rush   The ASX has fall...

ShareCafeThe Week that Was: February 6-10, 2023 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier to do so,...

ShareCafeMemphasys (ASX: MEM) Felix System Findings Memphasys (ASX: MEM) has announced the first publications of study findings by key opinion leaders of the Felix System. Memphasys (ASX: MEM) Felix System FindingsFinance News Network

ShareCafeASX closes 0.46% lower after RBAs 25 basis point hike by Peter Milios   The Reserve Bank of Australia has raised the official interest rate for the ninth consecutive time to 3.35 per cent. The bank indicated that more rate hikes ma...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] In vitro results from study findings on the Felix system developed by reproductive biotechnology company Memphasys (ASX: MEM) have demonstrated it can outperform conve...

Creso looks to potentially spin out psychedelic subsidiary  Two studies show Memphasys’ Felix reproductive tech outperforms WOA’s Dirty Clean Food brand nabs WHSmith retail deal   Yesterday the big news in the health sector was the Thera...

ShareCafeASX up 0.12% at noon as investors await this afternoon’s RBA meeting by Peter Milios   Investors are cautious as they await the outcome of the Reserve Bank’s meeting and examine local earnings updates. As a result, the Australian s...

ShareCafeStocks of the Hour: C29, EVR, MEM                    C29 Metals (ASX:C29) advises that drilling at their Pocitos 7 project in Argentina has concluded at 420 metres, with a packer test intercepting a deep aquifer from 370-400...

07 Feb 2023 - A snapshot of the stocks on the move featuring C29 Metals (ASX:C29), EV Resources (ASX:EVR) and Memphasys (ASX:MEM).

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

The ASX 200 rose a tidy 1.29% today with all sectors in the green ABS releases Aussie migrant data employment outcomes for the first time  ACCC gives the thumbs down to Telstra and TPG’s merger plans   The ASX 200 gained 1.29% today and...

The ASX 200 was in the red again, down 0.21% today 9 out 11 sectors finished lower led by Real Estate, with Energy and Materials gaining Stockmarkets head into the festive period in a downbeat mood, Oanda says   The ASX 200 was down 0.21%...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Wall St surged after a media report signalled the Fed might be slowing down its rate hikes from December Snap Inc plunged 28% on a bad quarter Tuesday’s Federal Budget will be the market’s focus this week Local shares are set to open shar...

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Small cap index up 1.1%, stronger than benchmark, but both do good, run hard.   Wall Street snaps 3-day losing streak, China could be back in stimmy mode Uranium’s gone insanium   The ASX 200 is up 0.7% and the Emerging Companies (XEC) in...

Small caps and benchmark down over 1% All sectors retreat on ill-winds blowing in from the states Tinkler is back   The ASX 200 has started a new week with its worst session since early July. While that can be pinned on a shift in US sent...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Small caps creep up 0.018%, ASX 200 stays flat Energy sector jumps with Karoon Energy and Terracom both up 7%+ The RBA is aiming for a soft landing for the economy   The ASX 200 was unchanged today with only six out of eleven sectors hig...

The ASX200 is down 0.24% dragged down by the tech sector Eight out of eleven sectors were lower, with Tech leading the losers CBA says the unemployment rate is at its lowest in 48 years   Despite creeping up earlier in the week the ASX 20...

The ASX200 is up 0.31% with the ABS reporting strong wage growth Seven out of eleven sectors were higher, with consumer staples leading the charge Real wages of Australians are going backwards due to the rising cost of living   The ASX 2...

Reproduction biotechnology and bio-separations company Memphasys (MEM) launches a $3.36 million capital raising The raise will comprise a $1.6 million placement and a $1.76 million non-renounceable entitlement offer The placement funds wil...

ASX 200 is up 0.2% and the XEC is down -0.2% Tension stateside ahead of FOMC decision, EU markets to start flat CPI at 6.1% is better than feared but enough to move the RBA next Tuesday And a crack team of small caps broke out of the ordin...

Reproduction biotechnology and bio-separations company Memphasys (MEM) enters a mid-week trading halt ahead of a capital raising The company will remain in the trading halt until Friday, July 29, or when further details are released to the...

While the bigger end of the towns tides out pre-earnings blackouts, small caps are making the most of ASX’s green days and fronting investors with cash calls. 

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Sydney biotechnology company Memphasys has passed another milestone on the route to commercialising its unique reproductive technology device, enrolling and treating the first couple in its new clinical study.